Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac arrest.

Trial Profile

Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac arrest.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Angina pectoris; Myocardial infarction
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 16 Jan 2015 Planned End Date changed from 28 Nov 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
    • 16 Jan 2015 Planned primary completion date changed to 1 Jul 2016, according to ClinicalTrials.gov record.
    • 16 Jan 2015 Planned initiation date changed to 1 Jan 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top